U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma soared 157%. Okta and Veeva Systems also rose. Build-A-Bear Workshop and Healthequity fell on earnings...

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.read more...

The market is getting a fresh reminder that the biggest opportunities are increasingly being built around AI, cybersecurity, advanced medicine and the infrastructure required to commercialize them. Propanc Biopharma (NASDAQ:PPCB), Celularity (NASDAQ:CELU), NeOnc Technologies (NASDAQ:NTHI), Salesforce (NYSE:CRM), CrowdStrike (NASDAQ:CRWD), and Okta (NASDAQ:OKTA).

US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings. Propanc Biopharma up 211%, VolitionRX up 86%, Mint Incorporation up 74%, Alpha Modus down 25%, Change...

Propanc Biopharma (NASDAQ:PPCB) is moving into a potentially important moment for its lead cancer candidate PRP, as new preclinical data arrive just as the pancreatic-cancer treatment landscape is undergoing a major transformation.

Propanc Biopharma announced the approval of a share buyback program worth up to $5 million.

For early-stage life sciences plays, deploying capital into a buyback program serves to validate management's view of a company's pipeline value. Today, an international developer focused on treating metastatic solid-tumor cancers triggered a triple-digit single-session market rally following a dual operational and capital-allocation update. Propanc Biopharma, Inc. (Nasdaq: PPCB) surged in Wednesday trading announcing its board of directors approved a $5.0M common-stock repurchase program. Management explicitly framed the capital-return initiative alongside core execution milestones for ...

For early-stage life sciences plays, deploying capital into a buyback program serves to validate management's view of a company's pipeline value. Today, an international developer focused on treating metastatic solid-tumor cancers triggered a triple-digit single-session market rally following a dual operational and capital-allocation update. Propanc Biopharma, Inc. (Nasdaq: PPCB) surged in Wednesday trading announcing its board of directors approved a $5.0M common-stock repurchase program. Management explicitly framed the capital-return initiative alongside core execution milestones for ...

Today's market action highlighted a familiar theme across the small-cap landscape: investors continue searching for transformative growth stories amid a market increasingly driven by company-specific catalysts. $TGNT, $TOVX, $MGNI, $PPCB, $MASK